ROCKET PHARMACEUTICALS INC
NASDAQ: RCKT (Rocket Pharmaceuticals, Inc.)
Kemas kini terakhir: 1 jam lalu3.50
0.02 (0.57%)
| Penutupan Terdahulu | 3.48 |
| Jumlah Dagangan | 1,858,152 |
| Harga / Buku (P/B) | 1.04 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -2.63 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 6.15% |
| Nisbah Semasa (MRQ) | 9.19 |
| Aliran Tunai Operasi (OCF TTM) | -208.66 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -109.28 M |
| Pulangan Atas Aset (ROA TTM) | -34.80% |
| Pulangan Atas Ekuiti (ROE TTM) | -60.45% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Rocket Pharmaceuticals, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -2.5 |
| Purata | -2.50 |
|
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 2.73% |
| % Dimiliki oleh Institusi | 93.45% |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| WILSON MARTIN | - | 3.35 | -75,364 | -252,469 |
| Jumlah Keseluruhan Kuantiti Bersih | -75,364 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -252,469 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 3.35 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| WILSON MARTIN | Pegawai | 11 Sep 2026 | Jual (-) | 75,364 | 3.35 | 252,469 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |